Please use this identifier to cite or link to this item:
https://hdl.handle.net/1959.11/21266
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Opriessnig, Tanja | en |
dc.contributor.author | Gerber, Priscilla Freitas | en |
dc.contributor.author | Xiao, Chao-Ting | en |
dc.contributor.author | Mogler, Mark | en |
dc.contributor.author | Halbur, Patrick G | en |
dc.date.accessioned | 2017-06-06T09:25:00Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Vaccine, 32(2), p. 230-237 | en |
dc.identifier.issn | 1873-2518 | en |
dc.identifier.issn | 0264-410X | en |
dc.identifier.uri | https://hdl.handle.net/1959.11/21266 | - |
dc.description.abstract | During 2012 and 2013, an apparent increase in porcine circovirus associated disease occurred in the USA. A variant PCV2b strain designated mPCV2b was recovered from many of these cases. This raised concerns of a decrease in efficacy of commercially available PCV2 vaccines. The objective of this study was to compare the ability of a commercial PCV2a-based vaccine and an experimental mPCV2b-based vaccine to control mPCV2b-associated disease, lesions, and viremia in a challenge model. Twenty-six caesarian-derived, colostrum-deprived pigs were randomly assigned to one of four groups: (1) vaccinated with a commercial PCV2a-based vaccine and challenged (PCV2a-VAC; n= 7), (2) vaccinated with an experimental mPCV2b-based vaccine and challenged (mPCV2b; n= 7), (3) sham-vaccinated with saline and challenged (positive controls; n= 7), and (4) sham-vaccinated with saline without challenge (negative controls; n= 5). Vaccination was done on D0 and D14, challenge was done on D28 using a tissue homogenate containing PRRSV and mPCV2b and the experiment was terminated on D49. Among the challenged pigs, 47.6% (10/21) developed severe clinical disease and either died or had to be humanely euthanized between D39 and D48 (11-20 days after challenge). PCV2 viremia was almost completely absent in the vaccinated groups regardless of vaccine type except for two PCV2a-vaccinated pigs which had detectable PCV2 DNA levels on individual days after challenge. Microscopic lesions typical of PCV2 infection were limited to the positive control group which developed mild-to-severe lesions associated with low-to-abundant PCV2 antigen. Under the conditions of this study, PCV2 vaccines regardless of PCV2 type were effective against mPCV2b challenge. | en |
dc.language | en | en |
dc.publisher | Elsevier Ltd | en |
dc.relation.ispartof | Vaccine | en |
dc.title | A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain | en |
dc.type | Journal Article | en |
dc.identifier.doi | 10.1016/j.vaccine.2013.11.010 | en |
dc.subject.keywords | Veterinary Medicine | en |
dc.subject.keywords | Veterinary Virology | en |
dc.subject.keywords | Veterinary Immunology | en |
local.contributor.firstname | Tanja | en |
local.contributor.firstname | Priscilla Freitas | en |
local.contributor.firstname | Chao-Ting | en |
local.contributor.firstname | Mark | en |
local.contributor.firstname | Patrick G | en |
local.subject.for2008 | 070712 Veterinary Virology | en |
local.subject.for2008 | 070706 Veterinary Medicine | en |
local.subject.for2008 | 070705 Veterinary Immunology | en |
local.subject.seo2008 | 830308 Pigs | en |
local.profile.school | School of Environmental and Rural Science | en |
local.profile.email | pgerber2@une.edu.au | en |
local.output.category | C1 | en |
local.record.place | au | en |
local.record.institution | University of New England | en |
local.identifier.epublicationsrecord | une-chute-20170602-153747 | en |
local.publisher.place | United Kingdom | en |
local.format.startpage | 230 | en |
local.format.endpage | 237 | en |
local.identifier.scopusid | 84890554909 | en |
local.peerreviewed | Yes | en |
local.identifier.volume | 32 | en |
local.identifier.issue | 2 | en |
local.contributor.lastname | Opriessnig | en |
local.contributor.lastname | Gerber | en |
local.contributor.lastname | Xiao | en |
local.contributor.lastname | Mogler | en |
local.contributor.lastname | Halbur | en |
dc.identifier.staff | une-id:pgerber2 | en |
local.profile.orcid | 0000-0002-8343-8299 | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.identifier.unepublicationid | une:21458 | en |
local.identifier.handle | https://hdl.handle.net/1959.11/21266 | en |
dc.identifier.academiclevel | Academic | en |
local.title.maintitle | A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain | en |
local.output.categorydescription | C1 Refereed Article in a Scholarly Journal | en |
local.search.author | Opriessnig, Tanja | en |
local.search.author | Gerber, Priscilla Freitas | en |
local.search.author | Xiao, Chao-Ting | en |
local.search.author | Mogler, Mark | en |
local.search.author | Halbur, Patrick G | en |
local.uneassociation | Unknown | en |
local.year.published | 2014 | en |
local.subject.for2020 | 300914 Veterinary virology | en |
local.subject.for2020 | 300907 Veterinary medicine (excl. urology) | en |
local.subject.for2020 | 300906 Veterinary immunology | en |
local.subject.seo2020 | 100410 Pigs | en |
Appears in Collections: | Journal Article |
Files in This Item:
File | Description | Size | Format |
---|
Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.